Compared with those who received placebo, the patients who received GLP-1 receptor agonists were less likely to experience serious and nonserious respiratory, skin and subcutaneous, musculoskeletal, vascular and COVID-19 infections
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: observations From the SAVOR-TIMI 53 Trial
It said it is also "thought to act as an anti-inflammatory, antioxidant and anti-cancer substance." It's effects on insulin and gut microbiota could be responsible for its potential weight-loss benefits, per the site
I still wholeheartedly believe in tracking macros and the workouts that I do and my classes
It was developed back in 2012, as a treatment for people with type 2 diabetes, but it took almost 5 years before it was FDA-approved for use